TyraTech, Inc. (AIM: TYR and TYRU), a life sciences company focused on nature-derived insect and parasite control products, is pleased to announce that it has secured listings for its Vamousse Treatment product with the CVS Pharmacy Group in the USA.
CVS Pharmacy is the second largest pharmacy chain after Walgreens in the United States, with more than 7,600 stores and 100 million American customers each year. This listing, which follows the recent announcement of deals with the top three pharmaceutical distributors in the USA, represents a further key milestone for the roll-out of TyraTech’s Vamousse products in America. It is expected that the Treatment product will be available in the majority of CVS stores nationwide in the USA from the end of April 2015.
In addition to the progress in the USA, we are pleased to announce positive developments in our UK distribution network also. Tesco, which had until recently been selling the Vamousse Treatment product through its pharmacy counters, will also place the product into open shelving, making it more accessible and visible to customers. Tesco has also confirmed separately, that it will almost double the number of stores stocking TyraTech’s Vamousse Treatment product.
Bruno Jactel, Chief Executive Officer, said: “The CVS listing is probably our most important milestone this year as it firmly establishes our product in the pharmacy segment in the USA and significantly enhances the profile of our brand. I would like to thank our partner, the Greenwood Group, which has been instrumental in establishing the commercial relationship with CVS and our retail partners in the USA. Together with the recent announcement of the three biggest pharmaceutical distributors in the USA, and Lloyds and Day Lewis in the UK, we are very excited by the growth opportunities presented by the continually expanding distribution network for Vamousse products.”
Further information on Vamousse® is available on the Company’s website at http://www.vamousselice.com/
For further information please contact:
Bruno Jactel, Chief Executive Officer
Vincent Morgus, Chief Financial Officer and Treasurer
|Tel: +1 919 415 4340
Tel: +1 919 415 4287
|SPARK Advisory Partners Limited, Nominated Adviser
Matt Davis / Mark Brady
|Tel: +44 203 368 3551
Tel: +44 203 368 3552
|Allenby Capital Limited , Joint Broker
|Tel: +44 20 3328 5656|
|Whitman Howard Limited, Joint Broker
Ranald McGregor-Smith/ Niall Devins
|Tel: +44 20 7659 1240|
|Walbrook, Financial PR and IR
Nick Rome/ Guy McDougall
|Tel: +44 20 7933 8790|